Evidence map›Paper›PMID 29211497›Full record

ArticleAmerican journal of respiratory cell and molecular biology2018

The Rho Kinase Isoforms ROCK1 and ROCK2 Each Contribute to the Development of Experimental Pulmonary Fibrosis.

Rachel S Knipe, Clemens K Probst, David Lagares, Alicia Franklin, Jillian J Spinney, Patricia L Brazee, Paula Grasberger, Linlin Zhang, Katharine E Black, Norihiko Sakai and 4 more

Abstract read
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 117 citations in OpenAlex.

  1. Review
  2. Article
  3. Mechanobiology and Resolution of Lung Fibrosis.Annual review of physiology · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Pulmonary Fibrosis-Focusing on the Future: Aspen Lung Conference 2024 Summary.American journal of respiratory cell and molecular biology · 2025
    Article
  9. Mechanosensing Pathways in the Progression of Pulmonary Fibrosis.Current opinion in biomedical engineering · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Paving the ROCKy Path to Novel Antifibrotics.American journal of respiratory cell and molecular biology · 2024
    Article
  19. Review
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Rachel S Knipe1 Division of Pulmonary and Critical Care Medicine.ORCID 0000-0002-4337-5748
Clemens K Probst1 Division of Pulmonary and Critical Care Medicine.
David Lagares1 Division of Pulmonary and Critical Care Medicine.
Alicia Franklin1 Division of Pulmonary and Critical Care Medicine.
Jillian J Spinney1 Division of Pulmonary and Critical Care Medicine.
Patricia L Brazee4 Division of Pulmonary Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Paula Grasberger1 Division of Pulmonary and Critical Care Medicine.
Linlin Zhang5 Division of Cardiology, Department of Medicine, University of Chicago, Chicago, Illinois.
Katharine E Black1 Division of Pulmonary and Critical Care Medicine.
Norihiko Sakai6 Division of Nephrology and.
Barry S Shea8 Division of Pulmonary, Critical Care and Sleep Medicine, Rhode Island Hospital and Alpert Medical School, Providence, Rhode Island.
James K Liao5 Division of Cardiology, Department of Medicine, University of Chicago, Chicago, Illinois.
Benjamin D Medoff1 Division of Pulmonary and Critical Care Medicine.
Andrew M Tager1 Division of Pulmonary and Critical Care Medicine.
Harvard University · USUniversity of Illinois Chicago · USNorthwestern University · USPediatric Nephrology of Alabama · USRhode Island Hospital · US

Funding

Research Training in Rheumatology at Massachusetts General HospitalT32AR007258 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI ANDREW D LUSTER · 1986 to 2026
$6.9M
LIPOPROTEINS EFFECTS ON G PROTEIN FUNCTIONR01HL052233 · NHLBI · UNIVERSITY OF CHICAGO · PI LIAO, JAMES KUANG-JAN · 1995 to 2016
$5.3M
TRAINING GRANT IN LUNG CELL &MOLECULAR BIOLOGYT32HL007874 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MEDOFF, BENJAMIN DAVID · 1997 to 2011
$4.1M
Targeting Cell-specific Functions of the Rho Kinase Pathway in Pulmonary FibrosisR01HL133153 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MCCARTHY, JASON R., MEDOFF, BENJAMIN DAVID · 2016 to 2019
$2.7M
Mechanisms Underlying Vascular AgingR01HL136962 · NHLBI · UNIVERSITY OF CHICAGO · PI LIAO, JAMES KUANG-JAN · 2018 to 2021
$1.8M
Role and regulation of vascular permeability in pulmonary fibrosisK08HL140175 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI KNIPE, RACHEL S · 2018 to 2022
$864k
NHLBI NIH HHS K08 HL140175NHLBI NIH HHS R01 HL052233NHLBI NIH HHS R01 HL133153NHLBI NIH HHS R01 HL136962NHLBI NIH HHS T32 HL007874NIAMS NIH HHS T32 AR007258
6 · The paper itself

Abstract

Pulmonary fibrosis is thought to result from dysregulated wound repair after repetitive lung injury. Many cellular responses to injury involve rearrangements of the actin cytoskeleton mediated by the two isoforms of the Rho-associated coiled-coil-forming protein kinase (ROCK), ROCK1 and ROCK2. In addition, profibrotic mediators such as transforming growth factor-β, thrombin, and lysophosphatidic acid act through receptors that activate ROCK. Inhibition of ROCK activation may be a potent therapeutic strategy for human pulmonary fibrosis. Pharmacological inhibition of ROCK using nonselective ROCK inhibitors has been shown to prevent fibrosis in animal models; however, the specific roles of each ROCK isoform are poorly understood. Furthermore, the pleiotropic effects of this kinase have raised concerns about on-target adverse effects of ROCK inhibition such as hypotension. Selective inhibition of one isoform might be a better-tolerated strategy. In the present study, we used a genetic approach to determine the roles of ROCK1 and ROCK2 in a mouse model of bleomycin-induced pulmonary fibrosis. Using ROCK1- or ROCK2-haploinsufficient mice, we found that reduced expression of either ROCK1 or ROCK2 was sufficient to protect them from bleomycin-induced pulmonary fibrosis. In addition, we found that both isoforms contribute to the profibrotic responses of epithelial cells, endothelial cells, and fibroblasts. Interestingly, ROCK1- and ROCK2-haploinsufficient mice exhibited similar protection from bleomycin-induced vascular leak, myofibroblast differentiation, and fibrosis; however, ROCK1-haploinsufficient mice demonstrated greater attenuation of epithelial cell apoptosis. These findings suggest that selective inhibition of either ROCK isoform has the potential to be an effective therapeutic strategy for pulmonary fibrosis.

Indexed as

AnimalsApoptosisBleomycinCapillary PermeabilityCell DifferentiationDisease Models, AnimalEndothelial CellsEpithelial CellsFibroblastsHaploinsufficiencyHumansLungMice, KnockoutMyofibroblastsPulmonary Fibrosisrho-Associated KinasesBleomycinrho-Associated KinasesROCK1 protein, humanRock1 protein, mouseROCK2 protein, humanRock2 protein, mouseapoptosismyofibroblastpulmonary fibrosisRho kinasevascular leak

Identifiers

PMID29211497
PMCPMC5894496
OpenAlexW2774399208

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.